Adaptive Biotechnologies (ADPT) EBIT (2018 - 2026)

Adaptive Biotechnologies has reported EBIT for 9 years, with the latest figure at -$19.2 million in Q1 2026.

• Quarterly EBIT rose 35.12% year-over-year to -$19.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$46.7 million (up 67.41% YoY) and the FY2025 annual result came in at -$57.1 million, up 64.86% from the prior year.
• EBIT slipped to -$19.2 million in Q1 2026 per ADPT's latest filing, from -$12.8 million in the prior quarter.
• Over five years, EBIT peaked at $10.3 million in Q3 2025 and troughed at -$71.1 million in Q4 2023.
• A 5-year average of -$39.2 million and a median of -$45.4 million in 2022 frame the typical range for EBIT.
• The sharpest annual moves came in 2023 and 2025: EBIT plunged 81.36% in 2023, then surged 131.53% in 2025.
• Over 5 years, EBIT stood at -$39.2 million in 2022, then slumped by 81.36% to -$71.1 million in 2023, then jumped by 52.39% to -$33.8 million in 2024, then jumped by 62.25% to -$12.8 million in 2025, then tumbled by 50.36% to -$19.2 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$19.2 million, -$12.8 million, and $10.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.